American Biochemical and Pharmaceuticals Limited 03071923 false 2023-10-01 2024-09-30 2024-09-30 The principal activity of the company is of import and export of chemical and pharmaceutical products. Digita Accounts Production Advanced 6.30.9574.0 true 03071923 2023-10-01 2024-09-30 03071923 2024-09-30 03071923 core:RetainedEarningsAccumulatedLosses 2024-09-30 03071923 core:ShareCapital 2024-09-30 03071923 core:CurrentFinancialInstruments 2024-09-30 03071923 core:CurrentFinancialInstruments core:WithinOneYear 2024-09-30 03071923 core:FurnitureFittings 2024-09-30 03071923 bus:SmallEntities 2023-10-01 2024-09-30 03071923 bus:AuditExemptWithAccountantsReport 2023-10-01 2024-09-30 03071923 bus:AbridgedAccounts 2023-10-01 2024-09-30 03071923 bus:SmallCompaniesRegimeForAccounts 2023-10-01 2024-09-30 03071923 bus:RegisteredOffice 2023-10-01 2024-09-30 03071923 bus:Director2 2023-10-01 2024-09-30 03071923 bus:Director3 2023-10-01 2024-09-30 03071923 bus:PrivateLimitedCompanyLtd 2023-10-01 2024-09-30 03071923 core:LicencesFranchises 2023-10-01 2024-09-30 03071923 core:FurnitureFittings 2023-10-01 2024-09-30 03071923 core:FurnitureFittingsToolsEquipment 2023-10-01 2024-09-30 03071923 countries:AllCountries 2023-10-01 2024-09-30 03071923 2023-09-30 03071923 core:FurnitureFittings 2023-09-30 03071923 2022-10-01 2023-09-30 03071923 2023-09-30 03071923 core:RetainedEarningsAccumulatedLosses 2023-09-30 03071923 core:ShareCapital 2023-09-30 03071923 core:CurrentFinancialInstruments 2023-09-30 03071923 core:CurrentFinancialInstruments core:WithinOneYear 2023-09-30 03071923 core:FurnitureFittings 2023-09-30 iso4217:GBP xbrli:pure

Registration number: 03071923

American Biochemical and Pharmaceuticals Limited

Annual Report and Unaudited Abridged Financial Statements

for the Year Ended 30 September 2024

 

American Biochemical and Pharmaceuticals Limited

Contents

Company Information

1

Abridged Balance Sheet

2 to 3

Notes to the Unaudited Abridged Financial Statements

4 to 7

 

American Biochemical and Pharmaceuticals Limited

Company Information

Directors

P Byrne

A Small

Registered office

Suite 1B1 Argyle House
Northside
Joel Street
Northwood Hills
HA6 1NW

Accountants

Ross + Partners
Chartered Certified Accountants
Suite 1B1 Argyle House
Northside
Joel Street
Northwood Hills
HA6 1NW

 

American Biochemical and Pharmaceuticals Limited

(Registration number: 03071923)
Abridged Balance Sheet as at 30 September 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

421

561

Current assets

 

Stocks

392,734

592,955

Debtors

246,031

370,255

Cash at bank and in hand

 

176,202

563,969

 

814,967

1,527,179

Creditors: Amounts falling due within one year

(34,340)

(321,674)

Net current assets

 

780,627

1,205,505

Total assets less current liabilities

 

781,048

1,206,066

Provisions for liabilities

(87)

(88)

Net assets

 

780,961

1,205,978

Capital and reserves

 

Called up share capital

100

100

Retained earnings

780,861

1,205,878

Shareholders' funds

 

780,961

1,205,978

For the financial year ending 30 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

All of the company’s members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

 

American Biochemical and Pharmaceuticals Limited

(Registration number: 03071923)
Abridged Balance Sheet as at 30 September 2024

Approved and authorised by the Board on 17 January 2025 and signed on its behalf by:
 

.........................................
A Small
Director

   
     
 

American Biochemical and Pharmaceuticals Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 30 September 2024

1

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Summary of disclosure exemptions

The company has taken advantage of the exemption under section 400 of the Companies act 2006 not to prepare consolidated accounts. The financial statements present information about the company as an individual entity and not about its group..

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

 

American Biochemical and Pharmaceuticals Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 30 September 2024

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixtures, fittings and equipment

25% reducing balance basis

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Licence fees

25% straight line basis

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

2

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2023 - 2).

 

American Biochemical and Pharmaceuticals Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 30 September 2024

3

Intangible assets

Total
£

Cost or valuation

At 1 October 2023

68,618

At 30 September 2024

68,618

Amortisation

At 1 October 2023

68,618

At 30 September 2024

68,618

Carrying amount

At 30 September 2024

-

 

American Biochemical and Pharmaceuticals Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 30 September 2024

4

Tangible assets

Fixtures and fittings
£

Total
£

Cost or valuation

At 1 October 2023

11,253

11,253

At 30 September 2024

11,253

11,253

Depreciation

At 1 October 2023

10,692

10,692

Charge for the year

140

140

At 30 September 2024

10,832

10,832

Carrying amount

At 30 September 2024

421

421

At 30 September 2023

561

561

5

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary of £1 each

100

100

100

100